Trial register facet
Trial records in cognitive performance and neuroprotection
18 records bearing on cognitive performance and neuroprotection.
Showing 0 records on this page
Records
18 documents
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| EXENATIDE-GE-PD | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 194 | 2025 | Moderate |
| EXENATIDE-GE-PD-DDIprogramme record | Exenatide | Phase 1 | Reported | Randomised crossover | — | 2025 | Very low |
| EXENATIDE-GE-PD-HEPATIC-IMPprogramme record | Exenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| GSH-PD-PH2 | Glutathione | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 45 | 2017 | Low |
| GSH-PD-PH2-ELDERLYprogramme record | Glutathione | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| GSH-PD-PH2-OLEprogramme record | Glutathione | Phase 2 | Reported | Single-arm open-label | — | 2017 | Very low |
| GSH-PD-PH2-ADHERENCEprogramme record | Glutathione | Phase 2 | Reported | Observational | — | 2017 | Very low |
| GSH-PD-PH2-BIOMARKERprogramme record | Glutathione | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| SEMAX-RU-COGNITIVE | Semax | — | No retrievable report | Observational | — | — | Not rated |
| SEMAX-RU-STROKE | Semax | — | No retrievable report | Observational | — | — | Not rated |
| SELANK-RU-ANXIETY | Selank | — | No retrievable report | Observational | — | — | Not rated |
| SEMAX-RU-COGNITIVE-QOLprogramme record | Semax | — | Reported | Randomised, double-blind, placebo-controlled | — | — | Very low |
| SEMAX-RU-STROKE-OLEprogramme record | Semax | — | Reported | Single-arm open-label | — | — | Very low |
| SELANK-RU-ANXIETY-DDIprogramme record | Selank | Phase 1 | Reported | Randomised crossover | — | — | Very low |
| SEMAX-RU-STROKE-ELDERLYprogramme record | Semax | — | Reported | Randomised, double-blind, placebo-controlled | — | — | Very low |
| SEMAX-RU-COGNITIVE-REGIONAL-JPprogramme record | Semax | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | — | Very low |
| SELANK-RU-ANXIETY-RENAL-IMPprogramme record | Selank | Phase 1 | Reported | Phase 1 ascending dose | — | — | Very low |
| SEMAX-RU-COGNITIVE-BODY-COMPprogramme record | Semax | — | Reported | Randomised, double-blind, placebo-controlled | — | — | Very low |